<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491400</url>
  </required_header>
  <id_info>
    <org_study_id>H-23185</org_study_id>
    <nct_id>NCT00491400</nct_id>
  </id_info>
  <brief_title>Effect of a Fibrate and a Statin on Endothelial Dysfunction</brief_title>
  <official_title>Effect of a Fibrate (Fenofibrate) and a Statin (Atorvastatin) and on Endothelial Dysfunction in Diabetes Mellitus and the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the effect of atorvastatin to the effect of fenofibrate on endothelial
      function in patients with diabetes mellitus or the metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare the effect of atorvastatin to the effect of fenofibrate on endothelial
      function in patients with diabetes mellitus or the metabolic syndrome. The study is a double
      blind, placebo controlled, crossover study with the order of treatment randomized. Patients
      will receive each treatment for 8 weeks with a 1 week rest period between treatment periods.
      Endothelial function will be tested using non-invasive techniques before and after each
      treatments. A total of 40 subjects with diabetes or the metabolic syndrome will be enrolled
      at Boston Medical Center.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment
  </why_stopped>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial Artery Flow-mediated Dilation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Endothelial function was assessed as brachial artery flow-mediated dilation (FMD) using ultrasound. FMD is calculated as the difference in brachial diameter during hyperemic flow and brachial diameter at baseline divided by brachial diameter at baseline and expressed as percent dilation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Lipids</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of the intervention on total cholesterol, HDL, and triglycerides</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Fenofibrate First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate 145 mg/day for 8 weeks First and Atorvastatin 20 mg/day for 8 weeks Second</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin First</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 20 mg/day for 8 weeks First and Fenofibrate 145 mg/day for 8 weeks Second</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate</intervention_name>
    <description>140 mg/day for 8 weeks</description>
    <arm_group_label>Fenofibrate First</arm_group_label>
    <arm_group_label>Atorvastatin First</arm_group_label>
    <other_name>Tricor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>20 mg/day for 8 weeks</description>
    <arm_group_label>Fenofibrate First</arm_group_label>
    <arm_group_label>Atorvastatin First</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than 30 years

          -  Adult-onset DM (defined as fasting glucose greater than 125 mg/dl or by ongoing
             treatment with an oral hypoglycemic agent) or metabolic syndrome (defined as at least
             3 of the following: 1. HDL less than 40 mg/dl for men or less than 50 mg/dl for women;
             2. triglycerides greater than 150 mg/dl; 3. waist circumference greater than 40 inches
             for men and greater than 35 inches for women; 4. fasting glucose greater than 100
             mg/dl).

          -  LDL cholesterol level less than 140 mg/dl

          -  Able to provide informed consent and complete study procedures

        Exclusion Criteria:

          -  Change in therapy for glucose control or blood pressure less than 1 month before entry

          -  Hemoglobin A1C greater than 8.0%.

          -  Renal insufficiency (serum creatinine greater than 1.6 mg/dl in men or 1.5 mg/dl in
             women.

          -  Any investigational drug less than 1 month before entry.

          -  Pregnancy (excluded by urine pregnancy test at study entry with ongoing use of
             reliable form of birth control) or lactation

          -  Liver function tests or serum creatinine kinase (CK) greater than 3 times upper limit
             of normal.

          -  Clinically evident major illnesses or other problem that would make participation
             inappropriate

          -  Clinical history of symptomatic cholelithiasis

          -  Patients with coronary artery disease, peripheral arterial disease, or cerebral
             vascular disease will not be enrolled if they are currently taking lipid-lowering
             therapy

          -  Patients taking more than 40 mg/day of atorvastatin will be excluded. There is no
             &quot;ceiling&quot; level for patients taking fibrates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph A Vita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>May 23, 2012</results_first_submitted>
  <results_first_submitted_qc>September 24, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2012</results_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>Joseph A. Vita</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>endothelium</keyword>
  <keyword>obesity</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients meeting the entry criteria were recruited at Boston Medical Center.</recruitment_details>
      <pre_assignment_details>101 patients were consented and underwent screening. 73 were excluded because testing demonstrated that they were ineligible. 28 Entered the study 9 withdrew from the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fenofibrate First</title>
          <description>Participants randomized to receive fenofibrate first and atorvastatin second</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin First</title>
          <description>Participants randomized to receive atorvastatin first and fenofibrate second</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started First Treatment</title>
              <participants_list>
                <participants group_id="P1" count="14">1 withdrew prior to starting fenofibrate</participants>
                <participants group_id="P2" count="13">None withdrew prior to starting atorvastatin</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed First Treatment</title>
              <participants_list>
                <participants group_id="P1" count="14">None withdrew during fenofibrate treatment (first treatment)</participants>
                <participants group_id="P2" count="9">4 withdrew during atorvastatin treatment (first treatment)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Second Treatment</title>
              <participants_list>
                <participants group_id="P1" count="12">2 withdrew during washout period</participants>
                <participants group_id="P2" count="9">None withdrew during the washout period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Finished Second Treatment</title>
              <participants_list>
                <participants group_id="P1" count="10">2 withdrew during atorvastatin treatment (second treatment)</participants>
                <participants group_id="P2" count="9">None withdrew during fenofibrate treatment (second treatment)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fenofibrate First</title>
          <description>Fenofibrate First and Atorvastatin Second</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin First</title>
          <description>Atorvastatin First and Fenofibrate Second</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Brachial Artery Flow-mediated Dilation</title>
        <description>Endothelial function was assessed as brachial artery flow-mediated dilation (FMD) using ultrasound. FMD is calculated as the difference in brachial diameter during hyperemic flow and brachial diameter at baseline divided by brachial diameter at baseline and expressed as percent dilation.</description>
        <time_frame>8 weeks</time_frame>
        <population>The number of participants is too few for meaningful analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate Treatment</title>
            <description>Effect of fenofibrate on brachial artery FMD</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin Treatment</title>
            <description>Effect of atorvastatin on brachial artery FMD</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Flow-mediated Dilation</title>
          <description>Endothelial function was assessed as brachial artery flow-mediated dilation (FMD) using ultrasound. FMD is calculated as the difference in brachial diameter during hyperemic flow and brachial diameter at baseline divided by brachial diameter at baseline and expressed as percent dilation.</description>
          <population>The number of participants is too few for meaningful analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Lipids</title>
        <description>Effect of the intervention on total cholesterol, HDL, and triglycerides</description>
        <time_frame>8 weeks</time_frame>
        <population>Enrollment was insufficient and there are too few subjects for meaningful analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Fenofibrate</title>
            <description>Effect of fenofibrate treatment on lipid profile</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin</title>
            <description>Effect of atorvastatin treatment on lipid profile</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Lipids</title>
          <description>Effect of the intervention on total cholesterol, HDL, and triglycerides</description>
          <population>Enrollment was insufficient and there are too few subjects for meaningful analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fenofibrate First</title>
          <description>Fenofibrate First and Atorvastatin Second</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin First</title>
          <description>Atorvastatin First and Fenofibrate Second</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to inadequate enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joseph A. Vita, MD</name_or_title>
      <organization>Boston University</organization>
      <phone>617-638-8700</phone>
      <email>jvita@bu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

